Investigation of Concomitant Use of Alzheimer's Disease Drugs with Sulfonylureas and Serious Hypoglycemia

Epidemiology. 2021 Jan;32(1):e3-e5. doi: 10.1097/EDE.0000000000001263.

Authors

Young Hee Nam¹, Colleen M Brensinger², Warren B Bilker², Charles E Leonard², Sean Hennessy²

Affiliations

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA.
² Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, hennessy@upenn.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Alzheimer Disease* / drug therapy
Alzheimer Disease* / epidemiology
Diabetes Mellitus, Type 2*
Humans
Hypoglycemia* / chemically induced
Hypoglycemia* / epidemiology
Hypoglycemic Agents / adverse effects
Pharmaceutical Preparations*
Sulfonylurea Compounds / adverse effects

Substances

Hypoglycemic Agents
Pharmaceutical Preparations
Sulfonylurea Compounds

Grants and funding